Floatz logo

Zenocutuzumab

Solid Tumours Harboring NRG1 Fusion

Partner Therapeutics, Inc.monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Solid Tumours Harboring NRG1 Fusion cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Zenocutuzumab is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
NRG1 FusionDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →